Drugs / EV71vac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03865238 | Apr 2019 → Apr 2021 | enterovirus infectious disease | Medigen Vaccine Biologics Corp. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EV71vac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03865238 ↗ |
| Modality | Vaccine | “EV71vac, an aluminium phosphate-adjuvanted inactivated EV71 vaccine” PMID 35427481 ↗ Apr 2022 |
| Route | Intramuscular | “via intramuscular injection 56 days apart” PMID 35427481 ↗ Apr 2022 |